Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
NEW YORK (Reuters Health) – Women treated with chest radiation in childhood or adolescence are at increased risk for breast cancer at a young age, and their risk…
NEW YORK (Reuters Health) – Active surveillance for renal cortical neoplasm is a “reasonable treatment option” in older patients with comorbid illness, according to a single-center report from…
NEW YORK (Reuters Health) – Sunitinib and sorafenib significantly increase patients’ risk of arterial thromboembolic events, according to a report in the March 29th online issue of the…
NEW YORK (Reuters Health) – Adjuvant chemotherapy, with or without postoperative radiotherapy, improves survival in patients with operable non-small-cell lung cancer, according to a March 24th online report…
NEW YORK (Reuters Health) – Ultrasound surveillance is a safe alternative to immediate resection for small testicular masses discovered incidentally, Canadian researchers report. Small testicular masses are occasionally…
NEW YORK (Reuters Health) – Gene expression-based signatures for lung cancer don’t seem any better than currently used prognostic factors at identifying patients who need adjuvant chemotherapy, researchers…
NEW YORK (Reuters Health) – High-potency, stereotactic body radiation therapy (SBRT) may improve survival for patients with medically inoperable early stage lung cancer, results of a multicenter phase…
NEW YORK (Reuters Health) – As first-line treatment for progressive chronic lymphocytic leukemia (CLL), cladribine and fludarabine are equally effective and safe in combination with cyclophosphamide, according to…
NEW YORK (Reuters Health) – A new biomarker – tumor-associated CD68+ macrophages — predicts poor outcomes in patients with classic Hodgkin’s lymphoma, new research indicates. About 20% of…
NEW YORK (Reuters Health) – There’s no good evidence that maintenance therapy improves the outcome of small-cell lung cancer (SCLC), according to a meta-analysis published February 25th in…
